1,6′-dithiolenalidomide | 1195729-60-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,6′-dithiolenalidomide
• 英文别名: 3-(4-amino-1-thioxo-1,3-dihydroisoindol-2-yl)-6-thioxo-piperidin-2-one；3-(4-Amino-1-thioxoisoindolin-2-yl)-6-thioxopiperidin-2-one；3-(7-amino-3-sulfanylidene-1H-isoindol-2-yl)-6-sulfanylidenepiperidin-2-one
• CAS: 1195729-60-2
• 化学式: C₁₃H₁₃N₃OS₂
• 分子量: 291.398
• InChiKey: VKEQCWZCXAGWJM-UHFFFAOYSA-N

物化性质

• 密度：
  1.51±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  来那度胺 在 劳森试剂 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 以43%的产率得到1,6′-dithiolenalidomide
  参考文献：
  名称：

  THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME

  摘要：

  提供了硫代异吲哚啉化合物，以及其药用可接受的盐、溶剂合物和立体异构体。公开了这些化合物的使用方法和药用组合物。

  公开号：

  US20090298882A1

文献信息

• THIO COMPOUNDS
  申请人：Greig Nigel H.

  公开号：US20130143922A1

  公开（公告）日：2013-06-06

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R 1 -R 8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.

  一个化合物，或其药学上可接受的盐或酯，其结构为：其中A、B和D分别为氧或硫，前提是A、B和D中至少有一个为硫；R1-R8分别独立地为氢、羟基、酰基、取代酰基、酰氧基、取代酰氧基、烷基、取代烷基、烯基、取代烯基、炔基、取代炔基、烷氧基、取代烷氧基、芳基、取代芳基、氨基、取代氨基、卤素、杂环烷基、取代杂环烷基、杂环芳基、取代杂环芳基或含硫基团。
• Thio compounds
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10220028B2

  公开（公告）日：2019-03-05

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.

  一种化合物，或其药学上可接受的盐或酯，其结构为： 其中 A、B 和 D 各自为氧或硫，条件是 A、B 和 D 中至少有一个是硫；R1-R8 各自独立地为氢、羟基、酰基、取代酰基、酰氧基、取代酰氧基、烷基、取代烷基、烯基、取代烯基、炔基、取代炔基、烷氧基、取代烷氧基、芳基、取代芳基、氨基、取代氨基、卤素、杂环烷基、取代杂环烷基、杂芳基、取代杂芳基或含硫基的基团。
• Thalidomide analogs and methods of use
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：US10730835B2

  公开（公告）日：2020-08-04

  Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.

  本研究公开了沙利度胺类似物和使用沙利度胺类似物的方法。所公开化合物的某些实施方案具有抗血管生成和/或抗炎活性。所公开化合物的某些实施方案不致畸。
• THALIDOMIDE ANALOGS AND METHODS OF USE
  申请人：The USA, as represented by the Secretary, Department of Health and Human Services

  公开号：US20200325102A1

  公开（公告）日：2020-10-15

  Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.
• US8927725B2
  申请人：——

  公开号：US8927725B2

  公开（公告）日：2015-01-06